Top

Published in:

Open Access 01-11-2020 | Breast Cancer | Review Article

Apolipoproteins, as the carrier proteins for lipids, are involved in the development of breast cancer

Authors: Y. Zhou, G. Luo

Published in: Clinical and Translational Oncology | Issue 11/2020

Abstract

Apolipoproteins, the key components of lipoproteins, play vital roles in the combination and transportation of lipids. Numerous research articles have accumulated solid evidence that lipoproteins are closely related to various types of tumorigenesis. In this review, we focused on the associations between several apolipoproteins and breast carcinoma and distinguished the effects and significance of apolipoproteins in different locations to validate their roles in breast carcinoma development. For example, apoD and apoE in serum are viewed as risk factors for breast carcinoma. ApoD, apoE and apoA-I in mammary tissues inhibit tumor growth. Moreover, apoB, apoJ and apoA-I have the potential to function as diagnostic or prognostic markers in the clinic. ApoEdp and apoJ treatment on breast carcinoma could significantly restrict tumor growth. In general, the aim of this review was to further analyze the associations between some members of the apolipoprotein family and breast cancer.

Cham BE. Importance of apolipoproteins in lipid metabolism. Chem Biol Interact. 1978;20(3):263–77.CrossRef

Camejo G, Suarez ZM, Munoz V. The apo-lipoproteins of human plasma high density lipoprotein: a study of their lipid binding capacity and interaction with lipid monolayers. Biochem Biophys Acta. 1970;218(1):155–66.CrossRef

Shore VG, Sae AS, Shore B. Surface exposure of apolipoproteins in high density lipoproteins. I. Reactivities with agarose-immobilized proteases. Biochimica Biophysica Acta. 1978;529(2):319–30.CrossRef

Xu N, Dahlback B. A novel human apolipoprotein (apoM). J Biol Chem. 1999;274(44):31286–90.CrossRef

Zhao SP, Verhoeven MH, Vink J, Hollaar L, van der Laarse A, de Knijff P, et al. Relationship between apolipoprotein E and low density lipoprotein particle size. Atherosclerosis. 1993;102(2):147–54.CrossRef

Wiwanitkit V. Obesity, HDL and breast cancer. Indian J Surg Oncol. 2012;3(4):286. https://doi.org/10.1007/s13193-012-0174-y.CrossRefPubMedPubMedCentral

Carr SS, Hooper AJ, Sullivan DR, Burnett JR. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology. 2019;51(2):148–54. https://doi.org/10.1016/j.pathol.2018.11.006.CrossRefPubMed

Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, et al. Body fatness and cancer-viewpoint of the IARC working group. N Engl J Med. 2016;375(8):794–8. https://doi.org/10.1056/NEJMsr1606602.CrossRefPubMedPubMedCentral

Sung H, Siegel RL, Torre LA, Pearson-Stuttard J, Islami F, Fedewa SA, et al. Global patterns in excess body weight and the associated cancer burden. CA Cancer J Clin. 2019;69(2):88–112. https://doi.org/10.3322/caac.21499.CrossRefPubMed

10.

Santos CRD, Fonseca I, Dias S, de Almeida JCM. Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression. BMC Cancer. 2014;14:132. https://doi.org/10.1186/1471-2407-14-132.CrossRef

11.

Ahn J, Lim U, Weinstein SJ, Schatzkin A, Hayes RB, Virtamo J, et al. Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(11):2814–21. https://doi.org/10.1158/1055-9965.EPI-08-1248.CrossRefPubMedPubMedCentral

12.

Simard J, Veilleux R, de Launoit Y, Haagensen DE, Labrie F. Stimulation of apolipoprotein D secretion by steroids coincides with inhibition of cell proliferation in human LNCaP prostate cancer cells. Can Res. 1991;51(16):4336–411.

13.

Yencilek F, Yilmaz SG, Yildirim A, Gormus U, Altinkilic EM, Dalan AB, et al. Apolipoprotein E genotypes in patients with prostate cancer. Anticancer Res. 2016;36(2):707–11.PubMed

14.

Koltai T. Clusterin: a key player in cancer chemoresistance and its inhibition. Onco Targets Ther. 2014;7:447–56. https://doi.org/10.2147/OTT.S58622.CrossRefPubMedPubMedCentral

15.

World Health Organization. Breast Cancer. In: Breast. 2018. https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf. Accessed Mar 2019.

16.

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869–74. https://doi.org/10.1073/pnas.191367098.CrossRefPubMed

17.

Cho GJ, Lee JH, Park HT, Shin JH, Hong SC, Kim T, et al. Postmenopausal status according to years since menopause as an independent risk factor for the metabolic syndrome. Menopause. 2008;15(3):524–9. https://doi.org/10.1097/gme.0b013e3181559860.CrossRefPubMed

18.

Buttros Dde A, Nahas EA, Vespoli Hde L, Uemura G, de Almeida BR, Nahas-Neto J. Risk of metabolic syndrome in postmenopausal breast cancer survivors. Menopause. 2013;20(4):448–54. https://doi.org/10.1097/gme.0b013e318272bd4a.CrossRefPubMed

19.

Cedo L, Reddy ST, Mato E, Blanco-Vaca F, Escola-Gil JC. HDL and LDL: potential new players in breast cancer development. J Clin Med. 2019. https://doi.org/10.3390/jcm8060853.CrossRefPubMedPubMedCentral

20.

Diez-Itza I, Vizoso F, Merino AM, Sanchez LM, Tolivia J, Fernandez J, et al. Expression and prognostic significance of apolipoprotein D in breast cancer. Am J Pathol. 1994;144(2):310–20.PubMedPubMedCentral

21.

Lin X, Hong S, Huang J, Chen Y, Chen Y, Wu Z. Plasma apolipoprotein A1 levels at diagnosis are independent prognostic factors in invasive ductal breast cancer. Discov Med. 2017;23(127):247–58.PubMed

22.

McConathy WJ, Alaupovic P. Isolation and partial characterization of apolipoprotein D: a new protein moiety of the human plasma lipoprotein system. FEBS Lett. 1973;37(2):178–82.CrossRef

23.

Do Carmo S, Seguin D, Milne R, Rassart E. Modulation of apolipoprotein D and apolipoprotein E mRNA expression by growth arrest and identification of key elements in the promoter. J Biol Chem. 2002;277(7):5514–23. https://doi.org/10.1074/jbc.M105057200.CrossRefPubMed

24.

Utermann G, Menzel HJ, Adler G, Dieker P, Weber W. Substitution in vitro of lecithin-cholesterol acyltransferase. Analysis of changes in plasma lipoproteins. Eur J Biochem. 1980;107(1):225–41.CrossRef

25.

Drayna D, Fielding C, McLean J, Baer B, Castro G, Chen E, et al. Cloning and expression of human apolipoprotein D cDNA. J Biol Chem. 1986;261(35):16535–9.PubMed

26.

Simard J, Dauvois S, Haagensen DE, Levesque C, Merand Y, Labrie F. Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer. Endocrinology. 1990;126(6):3223–311. https://doi.org/10.1210/endo-126-6-3223.CrossRefPubMed

27.

Simard J, de Launoit Y, Haagensen DE, Labrie F. Additive stimulatory action of glucocorticoids and androgens on basal and estrogen-repressed apolipoprotein-D messenger ribonucleic acid levels and secretion in human breast cancer cells. Endocrinology. 1992;130(3):1115–21. https://doi.org/10.1210/endo.130.3.1537279.CrossRefPubMed

28.

Soiland H, Soreide K, Janssen EA, Korner H, Baak JP, Soreide JA. Emerging concepts of apolipoprotein D with possible implications for breast cancer. Cell Oncol. 2007;29(3):195–209.PubMedPubMedCentral

29.

Sanchez LM, Diez-Itza I, Vizoso F, Lopez-Otin C. Cholesterol and apolipoprotein D in gross cystic disease of the breast. Clin Chem. 1992;38(5):695–8.CrossRef

30.

Haagensen DE Jr, Mazoujian G, Holder WD Jr, Kister SJ, Wells SA Jr. Evaluation of a breast cyst fluid protein detectable in the plasma of breast carcinoma patients. Ann Surg. 1977;185(3):279–85.CrossRef

31.

Lea OA, Kvinnsland S, Thorsen T. Progesterone-binding cyst protein in human breast tumor cytosol. Cancer Res. 1987;47(23):6189–92.PubMed

32.

Sivaraman VS, Wang H, Nuovo GJ, Malbon CC. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Investig. 1997;99(7):1478–83. https://doi.org/10.1172/JCI119309.CrossRefPubMed

33.

Sarjeant JM, Lawrie A, Kinnear C, Yablonsky S, Leung W, Massaeli H, et al. Apolipoprotein D inhibits platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferated by preventing translocation of phosphorylated extracellular signal regulated kinase 1/2 to the nucleus. Arterioscler Thromb Vasc Biol. 2003;23(12):2172–7. https://doi.org/10.1161/01.ATV.0000100404.05459.39.CrossRefPubMed

34.

Romano M, Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J. 2003;17(14):1986–95. https://doi.org/10.1096/fj.03-0053rev.CrossRefPubMed

35.

Matsuyama M, Yoshimura R, Mitsuhashi M, Tsuchida K, Takemoto Y, Kawahito Y, et al. 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway. Oncol Rep. 2005;14(1):73–9.PubMed

36.

Campisi J. Senescentcells, tumor suppression, and organismalaging: good citizens, bad neighbors. Cell. 2005;120:513–22.CrossRef

37.

Parrinello S, Coppe JP, Krtolica A, Campisi J. Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J Cell Sci. 2005;118(Pt 3):485–96. https://doi.org/10.1242/jcs.01635.CrossRefPubMedPubMedCentral

38.

Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451–67.CrossRef

39.

Soreide JA, Lea OA, Anda O, Skarstein A, Varhaug JE, Kvinnsland S. Progesterone-binding cyst protein (PBCP) in operable breast cancer: correlations with prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Anticancer Res. 1991;11(2):601–5.PubMed

40.

Blue ML, Williams DL, Zucker S, Khan SA, Blum CB. Apolipoprotein E synthesis in human kidney, adrenal gland, and liver. Proc Natl Acad Sci USA. 1983;80(1):283–7. https://doi.org/10.1073/pnas.80.1.283.CrossRefPubMed

41.

Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genom Hum Genet. 2000;1:507–37. https://doi.org/10.1146/annurev.genom.1.1.507.CrossRef

42.

Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240(4852):622–30.CrossRef

43.

Vogel T, Guo NH, Guy R, Drezlich N, Krutzsch HC, Blake DA, et al. Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation. J Cell Biochem. 1994;54(3):299–308. https://doi.org/10.1002/jcb.240540306.CrossRefPubMed

44.

Su WP, Chen YT, Lai WW, Lin CC, Yan JJ, Su WC. Apolipoprotein E expression promotes lung adenocarcinoma proliferation and migration and as a potential survival marker in lung cancer. Lung Cancer. 2011;71(1):28–33. https://doi.org/10.1016/j.lungcan.2010.04.009.CrossRefPubMed

45.

Chen YC, Pohl G, Wang TL, Morin PJ, Risberg B, Kristensen GB, et al. Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Can Res. 2005;65(1):331–7.

46.

Pencheva N, Tran H, Buss C, Huh D, Drobnjak M, Busam K, et al. Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis. Cell. 2012;151(5):1068–82. https://doi.org/10.1016/j.cell.2012.10.028.CrossRefPubMedPubMedCentral

47.

Bobin-Dubigeon C, Chauvin A, Brillaud-Meflah V, Boiffard F, Joalland MP, Bard JM. Liver X receptor (LXR)-regulated genes of cholesterol trafficking and breast cancer severity. Anticancer Res. 2017;37(10):5495–8. https://doi.org/10.21873/anticanres.11979.CrossRefPubMed

48.

Dobson CB, Sales SD, Hoggard P, Wozniak MA, Crutcher KA. The receptor-binding region of human apolipoprotein E has direct anti-infective activity. J Infect Dis. 2006;193(3):442–50. https://doi.org/10.1086/499280.CrossRefPubMed

49.

Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, et al. Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity. FEBS J. 2007;274(17):4511–25. https://doi.org/10.1111/j.1742-4658.2007.05981.x.CrossRefPubMed

50.

Bhattacharjee PS, Huq TS, Mandal TK, Graves RA, Muniruzzaman S, Clement C, et al. A novel peptide derived from human apolipoprotein E is an inhibitor of tumor growth and ocular angiogenesis. PLoS ONE. 2011;6(1):e15905. https://doi.org/10.1371/journal.pone.0015905.CrossRefPubMedPubMedCentral

51.

Niemi M, Kervinen K, Kiviniemi H, Lukkarinen O, Kyllonen AP, Apaja-Sarkkinen M, et al. Apolipoprotein E phenotype, cholesterol and breast and prostate cancer. J Epidemiol Community Health. 2000;54(12):938–9. https://doi.org/10.1136/jech.54.12.938.CrossRefPubMedPubMedCentral

52.

Zunarelli E, Nicoll JA, Migaldi M, Trentini GP. Apolipoprotein E polymorphism and breast carcinoma: correlation with cell proliferation indices and clinical outcome. Breast Cancer Res Treat. 2000;63(3):193–8.CrossRef

53.

Moysich KB, Freudenheim JL, Baker JA, Ambrosone CB, Bowman ED, Schisterman EF, et al. Apolipoprotein E genetic polymorphism, serum lipoproteins, and breast cancer risk. Mol Carcinog. 2000;27(1):2–9. https://doi.org/10.1002/(sici)1098-2744(200001)27:1%3c2:aid-mc2%3e3.0.co;2-w.CrossRefPubMed

54.

Porrata-Doria T, Matta JL, Acevedo SF. Apolipoprotein E allelic frequency altered in women with early-onset breast cancer. Breast Cancer. 2010;4:43–8.PubMed

55.

Uen YH, Liao CC, Lin JC, Pan YH, Liu YC, Chen YC, et al. Analysis of differentially expressed novel post-translational modifications of plasma apolipoprotein E in Taiwanese females with breast cancer. J Proteom. 2015;126:252–62. https://doi.org/10.1016/j.jprot.2015.05.038.CrossRef

56.

Xu X, Wan J, Yuan L, Ba J, Feng P, Long W, et al. Serum levels of apolipoprotein E correlates with disease progression and poor prognosis in breast cancer. Tumor Biol. 2016;37(12):15959–666. https://doi.org/10.1007/s13277-016-5453-8.CrossRef

57.

Yokoyama S, Fukushima D, Kupferberg JP, Kezdy FJ, Kaiser ET. The mechanism of activation of lecithin: cholesterol acyltransferase by apolipoprotein A-I and an amphiphilic peptide. J Biol Chem. 1980;255(15):7333–9.PubMed

58.

Lee-Rueckert M, Escola-Gil JC, Kovanen PT. HDL functionality in reverse cholesterol transport—challenges in translating data emerging from mouse models to human disease. Biochem Biophys Acta. 2016;1861(7):566–83. https://doi.org/10.1016/j.bbalip.2016.03.004.CrossRefPubMed

59.

Mineo C, Shaul PW. Novel biological functions of high-density lipoprotein cholesterol. Circ Res. 2012;111(8):1079–90. https://doi.org/10.1161/CIRCRESAHA.111.258673.CrossRefPubMedPubMedCentral

60.

Moore LE, Fung ET, McGuire M, Rabkin CC, Molinaro A, Wang Z, et al. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomark Prev. 2006;15(9):1641–6. https://doi.org/10.1158/1055-9965.EPI-05-0980.CrossRef

61.

Zamanian-Daryoush M, Lindner D, Tallant TC, Wang Z, Buffa J, Klipfell E, et al. The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects. J Biol Chem. 2013;288(29):21237–52. https://doi.org/10.1074/jbc.M113.468967.CrossRefPubMedPubMedCentral

62.

Cedo L, Garcia-Leon A, Baila-Rueda L, Santos D, Grijalva V, Martinez-Cignoni MR, et al. ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer. Sci Rep. 2016;6:36387. https://doi.org/10.1038/srep36387.CrossRefPubMedPubMedCentral

63.

Hamrita B, Ben Nasr H, Gabbouj S, Bouaouina N, Chouchane L, Chahed K. Apolipoprotein A1–75 G/A and +83 C/T polymorphisms: susceptibility and prognostic implications in breast cancer. Mol Biol Rep. 2011;38(3):1637–43. https://doi.org/10.1007/s11033-010-0274-0.CrossRefPubMed

64.

His M, Zelek L, Deschasaux M, Pouchieu C, Kesse-Guyot E, Hercberg S, et al. Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk. Eur J Epidemiol. 2014;29(2):119–32. https://doi.org/10.1007/s10654-014-9884-5.CrossRefPubMed

65.

Liu J-X, Yuan Q, Min Y-L, He Y, Xu Q-H, Li B, et al. Apolipoprotein AI and B as risk factors for development of intraocular metastasis in patients with breast cancer. Cancer Manag Res. 2019;11:2881–8. https://doi.org/10.2147/cmar.s191352.CrossRefPubMedPubMedCentral

66.

dos Santos CR, Domingues G, Matias I, Matos J, Fonseca I, de Almeida JM, et al. LDL-cholesterol signaling induces breast cancer proliferation and invasion. Lipids Health Dis. 2014;13:16. https://doi.org/10.1186/1476-511X-13-16.CrossRefPubMed

67.

Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013;342(6162):1094–8. https://doi.org/10.1126/science.1241908.CrossRefPubMedPubMedCentral

68.

Li J, Jia L, Zhao P, Jiang Y, Zhong S, Chen D. Stable knockdown of clusterin by vectorbased RNA interference in a human breast cancer cell line inhibits tumour cell invasion and metastasis. J Int Med Res. 2012;40(2):545–55. https://doi.org/10.1177/147323001204000216.CrossRefPubMed

69.

Niu Z, Li X, Hu B, Li R, Wang L, Wu L, et al. Small interfering RNA targeted to secretory clusterin blocks tumor growth, motility, and invasion in breast cancer. Acta Biochim Biophys Sin. 2012;44(12):991–8. https://doi.org/10.1093/abbs/gms091.CrossRefPubMed

70.

Bodde MC, Hermans MPJ, Jukema JW, Schalij MJ, Lijfering WM, Rosendaal FR, et al. Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up. Clin Res Cardiol. 2018. https://doi.org/10.1007/s00392-018-1381-5.CrossRefPubMedPubMedCentral

71.

Sun Y, Zhang J, Guo F, Zhao W, Zhan Y, Liu C, et al. Identification of apolipoprotein C-I peptides as a potential biomarker and its biological roles in breast cancer. Med Sci Monit. 2016;22:1152–60. https://doi.org/10.12659/msm.896531.CrossRefPubMedPubMedCentral

72.

Liu X, Wang Y, Qu H, Hou M, Cao W, Ma Z, et al. Associations of Polymorphisms of rs693 and rs1042031 in Apolipoprotein B GENE WITH RISK OF BREAST CANcer in Chinese. Jpn J Clin Oncol. 2013;43(4):362–8. https://doi.org/10.1093/jjco/hyt018.CrossRefPubMed

73.

Melvin JC, Garmo H, Holmberg L, Hammar N, Walldius G, Jungner I, et al. Glucose and lipoprotein biomarkers and breast cancer severity using data from the Swedish AMORIS cohort. BMC Cancer. 2017;17(1):246. https://doi.org/10.1186/s12885-017-3232-6.CrossRefPubMedPubMedCentral

74.

Song D, Yue L, Zhang J, Ma S, Zhao W, Guo F, et al. Diagnostic and prognostic significance of serum apolipoprotein C-I in triple-negative breast cancer based on mass spectrometry. Cancer Biol Ther. 2016;17(6):635–47. https://doi.org/10.1080/15384047.2016.1156262.CrossRefPubMedPubMedCentral

75.

Zhu Y, Luo G, Jiang B, Yu M, Feng Y, Wang M, et al. Apolipoprotein M promotes proliferation and invasion in non-small cell lung cancers via upregulating S1PR1 and activating the ERK1/2 and PI3K/AKT signaling pathways. Biochem Biophys Res Commun. 2018;501(2):520–6. https://doi.org/10.1016/j.bbrc.2018.05.029.CrossRefPubMed

76.

Luo G, Zhang X, Mu Q, Chen L, Zheng L, Wei J, et al. Expression and localization of apolipoprotein M in human colorectal tissues. Lipids Health Dis. 2010;9:102. https://doi.org/10.1186/1476-511X-9-102.CrossRefPubMedPubMedCentral

77.

Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstrom J, Sevvana M, et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci USA. 2011;108(23):9613–8. https://doi.org/10.1073/pnas.1103187108.CrossRefPubMed

78.

Wang F, Van Brocklyn JR, Edsall L, Nava VE, Spiegel S. Sphingosine-1-phosphate inhibits motility of human breast cancer cells independently of cell surface receptors. Can Res. 1999;59(24):6185–91.

79.

Mu QF, Luo GH, Chen LJ, Wei J, Zheng L, Zhang XY, et al. Apolipoprotein M expression in human colorectal cancer tissues and its clinicopathological relevance. Zhonghua wei chang wai ke za zhi Chin J Gastrointest Surg. 2012;15(8):855–8.

80.

Wolfrum C, Poy MN, Stoffel M. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med. 2005;11(4):418–22. https://doi.org/10.1038/nm1211.CrossRefPubMed

81.

Yu M-M, Yao S, Luo K-M, Mu Q-F, Yu Y, Luo G-H, et al. Apolipoprotein M increases the expression of vitamin D receptor mRNA in colorectal cancer cells detected with duplex fluorescence reverse transcription-quantitative polymerase chain reaction. Mol Med Rep. 2017;16(2):1167–72. https://doi.org/10.3892/mmr.2017.6716.CrossRefPubMedPubMedCentral

82.

Tavera-Mendoza LE, Westerling T, Libby E, Marusyk A, Cato L, Cassani R, et al. Vitamin D receptor regulates autophagy in the normal mammary gland and in luminal breast cancer cells. Proc Natl Acad Sci USA. 2017;114(11):E2186–E21942194. https://doi.org/10.1073/pnas.1615015114.CrossRefPubMed

Title: Apolipoproteins, as the carrier proteins for lipids, are involved in the development of breast cancer
Authors: Y. Zhou
G. Luo
Publication date: 01-11-2020
Publisher: Springer International Publishing
Keywords: Breast Cancer
Breast Cancer
Published in: Clinical and Translational Oncology / Issue 11/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-020-02354-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2020

Evaluating anti-tumor activity of palbociclib plus radiation in anaplastic and radiation-induced meningiomas: pre-clinical investigations

Urinary microRNAs expression in prostate cancer diagnosis: a systematic review

Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy

Incidence of venous thromboembolism in patients with colorectal cancer according to oncogenic status

The impact of surgical margin status on prostate cancer-specific mortality after radical prostatectomy: a systematic review and meta-analysis

Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer